Alpharadin
Everyman scientist at the ICR Dr Chris Parker is leading an international Phase III study into the drug alpharadin. More than 100 hospitals throughout the world, including more than 20 in the UK, are involved in this study.
The drug has been discovered, developed and licensed to therapeutics company, Algeta.
Alpharadin has completed Phase I/II studies in men with advanced and aggressive, hormone resistant prostate cancer which had spread to the bone. Taken in conjunction with conventional treatments, alpharadin has been shown (in these early studies) to have a benign side-effect profile and to extend the lives of patients.
This Phase III study is seeking 750 patients who have advanced, hormone resistant prostate cancer which has spread to the bone.
It is a randomised study, so 500 men will receive their existing treatment plus alpharadin and 250 patients will receive their existing treatment plus a placebo. Neither doctor nor patient will know whether or not the patient is receiving the placebo.
For more information about this trial including the specific eligibility criteria visit the US Nationals Institute of Health.
